May 10, 2017 12:05 pm UTC| Business
SAN DIEGO, May 10, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced...
May 10, 2017 12:05 pm UTC| Business
SAN DIEGO, May 10, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced...
May 10, 2017 12:05 pm UTC| Business
ST. PETERSBURG, Fla., May 10, 2017 -- Leading entertainment and lifestyle retailer, HSN, an operating segment of HSN, Inc. (Nasdaq:HSNI), and Time Inc.’s (NYSE:TIME) Food Wine announce a strategic alliance that will...
May 10, 2017 12:05 pm UTC| Business
ST. PETERSBURG, Fla., May 10, 2017 -- Leading entertainment and lifestyle retailer, HSN, an operating segment of HSN, Inc. (Nasdaq:HSNI), and Time Inc.’s (NYSE:TIME) Food Wine announce a strategic alliance that will...
May 10, 2017 12:05 pm UTC| Business
SAN DIEGO, May 10, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced...
May 10, 2017 12:05 pm UTC| Business
SAN DIEGO, May 10, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced...
Bellerophon Announces $3.0 Million Registered Direct Offering
May 10, 2017 12:04 pm UTC| Business
WARREN, N.J., May 10, 2017 -- Bellerophon Therapeutics,Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor...